Posters

26
Mar

POSTER – SOT HypoSkin Pharma Latch

Home / Resources / Posters Poster Replacing animal testing in local tolerance assessment of an injection device: Human ex vivo HypoSkin® model as a New Approach Methodology (NAM) Jérémy Argenty1, Clémence Letzelter1, Catherine Marques1, Sophie Abadie1, Alexia Sanchez1, Claire Gendrin1, Alexandra Ochando1, Adam Rock2, Ronan Byrne2, Pascal Descargues1 and Nicky Bertollo2 1Genoskin, 2Pharma Latch HypoSkin® is an ex vivo human skin NAM that
Read more
26
Mar

POSTER – SOT Hyposkin argenx

Home / Resources / Posters Poster HypoSkin® as a human-based NAMs platform for local toxicity and formulation safety assessment Julie Magerman1, Katarzyna Polak2, Ornella Binazon1, Michael Pastore2, Alexandra Ochando2 and Judith Baumeister1 1argenx, 2Genoskin Local Toxicity and Formulation Safety: An argenx Collaboration Study Formulation safety testing still relies heavily on in vivo studies due to limited validated in vitro alternatives. Genoskin’s HypoSkin® biostabilized ex vivo human skin
Read more
25
Sep

POSTER – Development of a Mast Cell Depleting Antibody for the Treatment of Mastocytosis

Prove ADCC Activityin real human skinFor therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential.Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear. HypoSkin® offers a solution Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm the
Read more
14
Oct

POSTER – Single-cell profiling of biostabilized natural human skin identifies mast cells as an important target of injected mRNA-1273 COVID-19 vaccine

Mast CellsSingle-cell profiling of biostabilized natural human skin identifies mast cells as an important target of injected mRNA-1273 COVID-19 vaccine. Research by M. Scholaert1,2, M. Peries2, E. Braun2, J. Martin1, N. Serhan1, A. Loste1, A. Bruner1, L. Basso1, E. Merle2, A. Trevisiol2, E. Pagès2 and N. Gaudenzio1,2 1Toulouse Insitute for Infectious and Inflammatory Diseases (Infinity), 2Genoskin The field of vaccination
Read more
14
Oct

POSTER – HypoSkin®, a new model to study microbiome

Skin MicrobiomeA fully functional ex vivo human skin model to study human skin microbiome Research by B. Coupe1, M. Pastore2, E. Pagès2, E. Braun2, A. Broha1, P. Descargues2 1Vaiomer, 2Genoskin The human skin is colonized by a diverse population of microorganisms. The symbiotic host-microorganism relationship can be affected by numerous endogenous and exogenous factors. This can result in skin disorders
Read more
14
Oct

POSTER – Woundskin®, an innovative model to study wound healing

Genoskin presents WoundSkin®, an infected wounded ex vivo skin model suited to assess the efficacy of wound-healing formulations.